The new Steam hardware is getting close, Arch Linux’s AUR is compromised, and curl is having a month off from vulnerability reports. Plus updates on using the Kagi search engine, retro handhelds, and 3D printing.
We get into the process of working on and with formal protocol specifications, something Andy is familiar with from his work on Matrix.
The new Steam hardware is getting close, Arch Linux’s AUR is compromised, and curl is having a month off from vulnerability reports. Plus updates on using the Kagi search engine, retro handhelds, and 3D printing.
We get into the process of working on and with formal protocol specifications, something Andy is familiar with from his work on Matrix.
Having recently moved house, Gary wonders how to reconfigure his homelab and network setup. Plus Shane is fed up with GitHub’s outages and formulates a plan to move away… somewhere…
NEW: Cancer drug Revlimid is one of the bestselling pharmaceutical products of all time, with total sales of over $100 billion. It also cost nearly $1,000 per pill, even though that same pill cost just 25 cents to make.
Listen to this episode of “Paper Trail” wherever you get your podcasts: https://www.propublica.org/podcast/revlimid-cancer-drugs-fda-healthcare?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
2.5 Admins 303: Denial of Secrets
People were locked out of their password managers to stop a brute force attack, Coreutils come to Windows, a FreeBSD PR effort backfires, and the best simple consumer WiFi gear.
2.5 Admins 303: Denial of Secrets
People were locked out of their password managers to stop a brute force attack, Coreutils come to Windows, a FreeBSD PR effort backfires, and the best simple consumer WiFi gear.
NEW: Cancer drug Revlimid is one of the bestselling pharmaceutical products of all time, with total sales of over $100 billion. It also cost nearly $1,000 per pill, even though that same pill cost just 25 cents to make.
Listen to this episode of “Paper Trail” wherever you get your podcasts: https://www.propublica.org/podcast/revlimid-cancer-drugs-fda-healthcare?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post